CooperCompanies (COO)
Develops contact lenses, fertility services and women’s-health medical devices.
Something off on this page? Send us feedback.
Develops contact lenses and myopia-management products through CooperVision, while CooperSurgical sells fertility, cryostorage, genomic, contraception and women’s-health devices and services. Contact lenses generate most revenue, with sales distributed across the Americas, Europe, the Middle East, Africa and Asia Pacific.
Operates through two medical-device businesses: CooperVision and CooperSurgical. CooperVision develops and manufactures daily, two-week and monthly contact lenses, including toric, multifocal and myopia-management products. Biofinity, MyDay and MiSight anchor a portfolio designed around broad prescription parameters and recurring replacement demand.
CooperSurgical supplies fertility clinics, OB/GYN offices, hospitals and surgery centers with IVF devices and consumables, donor gametes, cryostorage, genomic testing, contraception, and gynecology and obstetrics devices. Sales span the Americas, Europe, the Middle East, Africa and Asia Pacific, while contact lenses generate most revenue.
Manufacturing scale, practitioner education and a broad fitting range support execution across eye-care channels. Medical-device approvals, quality systems, fertility-treatment activity and sole-sourced materials for some silicone hydrogel lenses and IVF products remain structural dependencies.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | Mizuho Securities | Target | Target: $85 | Target: $75 |
| Sep 10, 2026 | William Blair | Downgrade | ||
| Sep 10, 2026 | UBS | Reiterate | Rating: —Target: — | Target: $66 |
| Sep 10, 2026 | Needham | Reiterate | Rating: —Target: $86 | Target: $73 |
| Sep 10, 2026 | Wells Fargo | Reiterate | Rating: —Target: $66 | Target: $61 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 31, 2026Cash & short-term investments $154.7M · Total debt $2.54B · Total assets $12.67B · Shareholders' equity $8.33B
- Revenue
- $1.07B
- Operating income
- $222.4M
- Net income
- $432.8M
HistoryDividendAnnual yield
| Institutions | 111.04% | 211.15M shares | |
|---|---|---|---|
| 684 holders · as of Jun 30, 2026 | |||
| Insiders | 1.05% | 1.99M shares | |
| 18 holders · as of Sep 17, 2026 | |||
| Adds to | 112.09% | ||
190.16M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 112.09%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.90% | 15.03M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.71% | 12.76M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.68% | 8.89M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.56% | 8.67M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 3.91% | 7.43M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Lawrence Erik Kurzius | director | +10,000 | $54.93 |
| Sep 14, 2026 | Walter M. Jr Rosebrough | director | +3,000 | $54.29 |
| Sep 11, 2026 | Walter M. Jr Rosebrough | director | +7,000 | $54.11 |
| Sep 14, 2026 | Lawrence Erik Kurzius | director | +10,000 | $53.92 |
| Sep 11, 2026 | Paul A. Keel | director | +4,701 | $53.18 |
- Johnson & Johnson
ACUVUE contact lenses and broad surgical devices overlap both segments
- Alcon
DAILIES, TOTAL, and PRECISION brands contest CooperVision lenses
- Bausch + Lomb
Biotrue, ULTRA, and SiHy Daily lens growth overlap contact lenses
- Medtronic
Surgical and gynecology devices overlap CooperSurgical medical devices
- Revvity
ViaCord cord-blood banking overlaps CooperSurgical cryostorage
- Organon
Nexplanon and fertility products overlap Paragard and fertility care
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CooperCompanies | $55.18 | +1.96% | $10.56B | 18.5 | 12.0 | 2.5 | +0.6% |
| Johnson & Johnson | $268.56 | −0.34% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Alcon | $65.48 | +0.94% | $31.64B | 49.9 | 17.2 | 2.9 | +7.5% |
| Bausch + Lomb | $17.22 | +2.50% | $6.00B | — | 17.2 | 1.1 | +9.1% |
| Medtronic | $91.27 | −0.52% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Revvity | $143.21 | −0.26% | $16.02B | 68.4 | 25.4 | 5.5 | −1.3% |
| Organon | $13.70 | +0.11% | $3.59B | 17.8 | 3.9 | 0.6 | +0.5% |
| Median | 31.2 | 17.2 | 3.0 | +7.0% |